...
首页> 外文期刊>The annals of pharmacotherapy >Ranitidine bismuth citrate in the treatment of Helicobacter pylori infection and duodenal ulcer.
【24h】

Ranitidine bismuth citrate in the treatment of Helicobacter pylori infection and duodenal ulcer.

机译:雷尼替丁柠檬酸铋治疗幽门螺杆菌感染和十二指肠溃疡。

获取原文
获取原文并翻译 | 示例
           

摘要

OBJECTIVE: To review the clinical pharmacology of ranitidine bismuth citrate in the treatment of Helicobacter pylori (HP) infection and duodenal ulcer. DATA SOURCES: A MEDLINE search of the English-language literature from 1992 to January 1997 was conducting using the key terms Tritec, ranitidine, and bismuth. References of articles pertaining to treatment of duodenal ulcer or HP were extensively searched for relevant sources. DATA EXTRACTION: All articles pertaining to ranitidine bismuth citrate were considered for inclusion, with emphasis placed on randomized, double-blind trials. Priority was placed on data pertaining to regimens that are currently approved by the Food and Drug Administration for the treatment of duodenal ulcer in conjunction with HP. DATA SYNTHESIS: Each tablet of ranitidine bismuth citrate 400 mg contains 162 mg of ranitidine base, 128 mg of trivalent bismuth, and 110 mg of citrate. It uses the acid-suppressive actions of ranitidine and the antimicrobial and mucosal protective effects of bismuth to eradicate HP. Ranitidine bismuth citrate in conjunction with clarithromycin represents one of four treatment regimens currently approved in the US for duodenal ulcer associated with HP infection. In four double-blind, randomized trials, this agent has achieved HP eradication rates of 73-94% and duodenal ulcer healing rates of 73-89%. It is given twice daily for 28 days, and is associated with very low rates of adverse effects. CONCLUSIONS: Relative to some therapeutic alternatives, ranitidine bismuth citrate plus clarithromycin may be simpler to take and have less adverse effects, but may be more expensive. Compared with omeprazole plus clarithromycin, it is less expensive, may have lower ulcer healing rates, but may be more effective in eradicating HP. The role of ranitidine bismuth citrate will continue to evolve as more patients are treated, and other regimens continue to be tested for duodenal ulcer healing and HP eradication.
机译:目的:探讨雷尼替丁柠檬酸铋铋治疗幽门螺杆菌(HP)感染和十二指肠溃疡的临床药理作用。资料来源:MEDLINE检索了1992年至1997年1月的英语文献,使用的关键词是Tritec,雷尼替丁和铋。广泛搜索有关十二指肠溃疡或HP的文章的参考文献以寻找相关来源。数据提取:所有与雷尼替丁柠檬酸铋有关的文章均被考虑纳入,重点放在随机,双盲试验上。优先考虑与食品和药物管理局当前批准的与HP一起治疗十二指肠溃疡的治疗方案有关的数据。数据合成:每片400毫克雷尼替丁柠檬酸铋含有162毫克雷尼替丁碱,128毫克三价铋和110毫克柠檬酸。它利用雷尼替丁的酸抑制作用以及铋的抗菌和粘膜保护作用来根除HP。雷尼替丁柠檬酸铋铋与克拉霉素一起代表了美国目前批准的与HP感染相关的十二指肠溃疡的四种治疗方案之一。在四项双盲,随机试验中,该药物的HP根除率达到73-94%,十二指肠溃疡治愈率达到73-89%。每天两次,持续28天,并且不良反应发生率非常低。结论:相对于某些替代疗法,雷尼替丁柠檬酸铋铋和克拉霉素可能更易于服用且不良反应较少,但可能更昂贵。与奥美拉唑加克拉霉素相比,它更便宜,溃疡愈合率更低,但在根除HP方面可能更有效。随着更多患者的接受治疗,雷尼替丁柠檬酸铋铋的作用将继续发展,并继续测试其他治疗十二指肠溃疡愈合和根除HP的方案。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号